Maxygen (MAXY)
Maxygen Current Ratio: 66.35
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MAXY Current Ratio Rankings
| Overall | 99th percentile | 11 of 4373 |
| Sector | 99th percentile | 1 of 852 in Services |
| Industry | 91st percentile | 1 of 12 in Research Services |
MAXY Current Ratio Range, Past 5 Years
| Minimum | 7.301 | Mar 2010 |
| Maximum | 66.35 | Mar 2012 |
| Average | 20.26 |
About Current Ratio
The current ratio measures a company's ability to pay short-term debts and other current liabilities (financial obligations lasting less than one year) by comparing current assets to current liabilities. Current assets are cash and any assets expected to be converted into cash within the next year. The ratio illustrates a company's ability to remain solvent.
A current ratio of 1 means that book value of current assets is exactly the same as book value of current liabilities. In general, investors look for a company with a current ratio of 2:1, meaning that it has twice as many current assets as current liabilities. A current ratio less than one indicates the company might have problems meeting short-term financial obligations. If the ratio is too high, the company may not be efficiently using its current assets or short term financing facilities.
Learn More
You may also be interested in these MAXY related companies
MAXY News
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
$MAXY forms bullish "Continuation Wedge" chart pattern. http://stks.co/3OAl
about 42 days ago by RecogniaEvents
about 42 days ago by RecogniaEvents
$MAXY http://stks.co/29DH vol laden nr7 friday w/ pos hard sell below $5.4
about 121 days ago by traderdigs
about 121 days ago by traderdigs
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
Nov 09, 4:30PM Business Wire
Nov 09, 4:30PM Business Wire
$MAXY set to rally after breaking out of long consolidation rectangle. Looks to close the December 2010 gap at $6.80
about 231 days ago by checkthetechs
about 231 days ago by checkthetechs
Maxygen announces final rejection of '804 patent in inter partes reexamination
Oct 10, 5:17PM FlyOnTheWall
Oct 10, 5:17PM FlyOnTheWall
Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding
Oct 10, 5:00PM Business Wire
Oct 10, 5:00PM Business Wire
Some Swings and Scalps for Today: $RCKB $IPAS $MAXY $DGII http://stk.ly/keEf56
about 348 days ago by SharePlanner
about 348 days ago by SharePlanner
=> $MAXY $5.23 LEE KENNETH B JR director P 3,000 @ $5.23 amnt $15,690 proc'd $0 6/1/2011
about 363 days ago by canarionyc
about 363 days ago by canarionyc
$MAXY--Director purchased 20,000 shares at $5.16. Last trade is $5.08. Nice float, decent avg volume. Do your own research.
about 373 days ago by MicroInsider
about 373 days ago by MicroInsider
$MAXY $5.08 STEIN ISAAC director P 20,000 @ $5.16 amnt $103,200 proc'd ($1,600) 5/19/2011
about 376 days ago by canarionyc
about 376 days ago by canarionyc
$MAXY tries for radiation exposure BARDA award w/ MAXY-34: http://stk.ly/jd0fhC Didn't a Canadian licensee already fail with this attempt?
about 391 days ago by BioDueDiligence
about 391 days ago by BioDueDiligence
$MAXY http://chart.ly/xbp2y4t Spec biotech showing tight weekly closes after big move; like to see this - good support
about 419 days ago by Kenshreve
about 419 days ago by Kenshreve
Astellas exercises option to buy out $MAXY JV for 76m http://stk.ly/egeX5B Nice deal, but makes the 20m deal w/ $CDXS look even worse
about 440 days ago by BioDueDiligence
about 440 days ago by BioDueDiligence
$MAXY 4q2010 results: http://stk.ly/dQTWE9 Does this structure and strategy make sense to anyone besides the 5 guys still getting paychecks?
about 448 days ago by BioDueDiligence
about 448 days ago by BioDueDiligence
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MAXY | 5.87 | +0.02 | +0.34% | 162.45M |
| LOGI | 10.77 | +0.15 | +1.41% | 1.832B |
| LOCM | 2.46 | +0.03 | +1.23% | 53.65M |
| LOAN | 1.08 | +0.00 | +0.00% | 4.666M |
| LO | 124.77 | -0.07 | -0.06% | 16.48B |
| LNT | 44.10 | +0.06 | +0.14% | 4.889B |
| KLIC | 10.89 | +0.07 | +0.65% | 797.65M |
| KLD | 57.54 | +0.47 | +0.83% | |
| KLAC | 46.84 | +0.69 | +1.50% | 7.695B |
| KKR | 12.17 | +0.47 | +4.02% | 2.711B |
